Anna R Carta

List of Publications by Year
in descending order

69 papers	3,511 citations	145106 33 h-index	156644 58 g-index
74 all docs	74 docs citations	74 times ranked	5004 citing authors

#	Article	IF	Citations
1	Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. Neurotherapeutics, 2022, 19, 305-324.	2.1	3
2	Nicotine, cocaine, amphetamine, morphine, and ethanol increase norepinephrine output in the bed nucleus of stria terminalis of freely moving rats. Addiction Biology, 2021, 26, e12864.	1.4	16
3	Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. Frontiers in Neuroscience, 2021, 15, 656921.	1.4	16
4	Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?. Frontiers in Neuroscience, 2021, 15, 657714.	1.4	13
5	Modeling Parkinsonâ€™s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human Î±-Synuclein Oligomers. International Journal of Molecular Sciences, 2020, 21, 8535.	1.8	24
6	Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 6745.	1.8	3
7	The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications. Progress in Brain Research, 2020, 252, 131-168.	0.9	21
8	Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2WD40 Genetic Model of Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 31.	1.7	13
9	Advances in modelling alpha-synuclein-induced Parkinsonâ€™s diseases in rodents: Virus-based models versus inoculation of exogenous preformed toxic species. Journal of Neuroscience Methods, 2020, 338, 108685.	1.3	16
10	Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?. Medical Hypotheses, 2020, 140, 109776.	0.8	75
11	Beneficial effects of curtailing immune susceptibility in an Alzheimerâ€™s disease model. Journal of Neuroinflammation, 2019, 16, 166.	3.1	27
12	Immunomodulatory drugs alleviate <scp>l</scp>â€dopaâ€induced dyskinesia in a rat model of Parkinson's disease. Movement Disorders, 2019, 34, 1818-1830.	2.2	44
13	Trimethyl Chitosan Hydrogel Nanoparticles for Progesterone Delivery in Neurodegenerative Disorders. Pharmaceutics, 2019, 11, 657.	2.0	26
14	Boosting phagocytosis and antiâ€inflammatory phenotype in microglia mediates neuroprotection by PPARÎ³ agonist MDG548 in Parkinson's disease models. British Journal of Pharmacology, 2018, 175, 3298-3314.	2.7	48
15	Neuroinflammation in l-DOPA-induced dyskinesia: beyond the immune function. Journal of Neural Transmission, 2018, 125, 1287-1297.	1.4	35
16	Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinsonâ€™s Disease?. Frontiers in Molecular Neuroscience, 2018, 11, 144.	1.4	130
17	Microglial phenotypes in Parkinsonâ€™s disease and animal models of the disease. Progress in Neurobiology, 2017, 155, 57-75.	2.8	202
18	<scp>l</scp>â€DOPAâ€induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?. European Journal of Neuroscience, 2017, 45, 73-91.	1.2	56

#	Article	IF	Citations
19	Role of Adenosine in the Basal Ganglia. Handbook of Behavioral Neuroscience, 2016, , 237-256.	0.7	0
20	Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l -DOPA delivery in the 6-OHDA model of Parkinson's disease. Experimental Neurology, 2016, 286, 83-92.	2.0	75
21	Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARÎ³ agonist in vitro and in MPTP-treated mice. Neuroscience, 2015, 302, 23-35.	1.1	37
22	Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiology of Disease, 2015, 74, 295-304.	2.1	51
23	Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinsonâ€™s disease. Expert Opinion on Investigational Drugs, 2015, 24, 219-227.	1.9	28
24	Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-Î³ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiology of Disease, 2014, 71, 280-291.	2.1	218
25	MPTP: Advances from an Evergreen Neurotoxin. , 2014, , 2099-2124.		0
26	The MPTP/Probenecid Model of Progressive Parkinsonâ€™s Disease. Methods in Molecular Biology, 2013, 964, 295-308.	0.4	26
27	Modulating Microglia Activity with PPAR-Î³ Agonists: A Promising Therapy for Parkinsonâ€™s Disease?. Neurotoxicity Research, 2013, 23, 112-123.	1.3	54
28	PPAR-γ: Therapeutic Prospects in Parkinson's Disease. Current Drug Targets, 2013, 14, 743-751.	1.0	62
29	The role of microgliaâ€“lymphocyte interaction in PD neuropathology. Basal Ganglia, 2012, 2, 123-130.	0.3	1
30	Nematicidal Activity of 2-Thiophenecarboxaldehyde and Methylisothiocyanate from Caper (<i>Capparis) Tj ETQq0 0 0 rgBT /Overlock 10 60, 7345-7351.	2.4	36
31	Dyskinesia in Parkinson's Disease Therapy. Parkinson's Disease, 2012, 2012, 1-2.	0.6	0
32	Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience, 2011, 194, 250-261.	1.1	125
33	Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?. Parkinson's Disease, 2011, 2011, 1-14.	0.6	37
34	Role of Adenosine in the Basal Ganglia. Handbook of Behavioral Neuroscience, 2010, , 201-217.	0.7	0
35	Pathophysiological roles for purines. Progress in Brain Research, 2010, 183, 183-208.	0.9	81
36	Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Experimental Neurology, 2010, 224, 395-402.	2.0	17

#	Article	IF	Citations
37	Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinsonâ€™s Disease. Neurotoxicity Research, 2009, 16, 127-139.	1.3	86
38	PPARâ€gammaâ€mediated neuroprotection in a chronic mouse model of Parkinsonâ€™s disease. European Journal of Neuroscience, 2009, 29, 954-963.	1.2	186
39	Inactivation of neuronal forebrain A_{2A} receptors protects dopaminergic neurons in a mouse model of Parkinsonâ€™s disease. Journal of Neurochemistry, 2009, 111, 1478-1489.	2.1	64
40	Adenosine A2A Receptors and Parkinsonâ€™s Disease. Handbook of Experimental Pharmacology, 2009, , 589-615.	0.9	102
41	Behavioural Correlates of Dopaminergic Agonistsâ€™ Dyskinetic Potential in the 6-OHDA-Lesioned Rat. Advances in Behavioral Biology, 2009, , 461-470.	0.2	0
42	Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6â€OHDA lesioned rat. Synapse, 2008, 62, 524-533.	0.6	40
43	Longâ€term increase in GAD67 mRNA expression in the central amygdala of rats sensitized by drugs and stress. European Journal of Neuroscience, 2008, 27, 1220-1230.	1.2	14
44	Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: Behavioural and biochemical evidence. Parkinsonism and Related Disorders, 2008, 14, S165-S168.	1.1	18
45	The 6-Hydroxydopamine model of parkinsonâ€™s disease. Neurotoxicity Research, 2007, 11, 151-167.	1.3	353
46	Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. Journal of the Neurological Sciences, 2006, 248, 48-52.	0.3	25
47	GABAA receptors mediate orexin-A induced stimulation of food intake. Neuropharmacology, 2006, 50, 16-24.	2.0	35
48	How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson??s disease?. Behavioural Pharmacology, 2006, 17, 393-402.	0.8	27
49	Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. Journal of Neurochemistry, 2006, 98, 1078-1089.	2.1	23
50	B67 INCREASE IN BASAL GAD67 mRNA EXPRESSION IN THE CENTRAL NUCLEUS OF THE AMYGDALA: A MARKER OF STRESS AND DRUG-INDUCED BEHAVIOURAL SENSITIZATION. Behavioural Pharmacology, 2005, 16, S87.	0.8	0
51	A89 CAFFEINE SENSITIZATION AND CROSS-SENSITIZATION WITH AMPHETAMINE: ASSOCIATION WITH POST-SYNAPTIC CHANGES IN RAT STRIATAL NEURONS. Behavioural Pharmacology, 2005, 16, S51.	0.8	0
52	Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment. European Journal of Neuroscience, 2005, 21, 1196-1204.	1.2	64
53	Changes in the Expression of Tonic and Phasic Neurochemical Markers of Activity in a Rat Model of L-DOPA Induced Dyskinesia. , 2005, , 371-378.		0
54	EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinsonâ€™s disease. Brain Research, 2003, 972, 177-185.	1.1	25

#	Article	IF	Citations
55	Selective modifications in GAD67 mRNA levels in striatonigral and striatopallidal pathways correlate to dopamine agonist priming in 6-hydroxydopamine-lesioned rats. European Journal of Neuroscience, 2003, 18, 2563-2572.	1.2	38
56	Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Experimental Neurology, 2003, 184, 679-687.	2.0	25
57	Ontogenesis of Leptin Receptor in Rat Leydig Cells1. Biology of Reproduction, 2003, 68, 1199-1207.	1.2	63
58	Adenosine A _{2A} and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology, 2003, 61, S39-43.	1.5	18
59	Modification of adenosine extracellular levels and adenosine A2A receptor mRNA by dopamine denervation. European Journal of Pharmacology, 2002, 446, 75-82.	1.7	71
60	Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittentL-dopa and A2A receptor blockade plusL-Dopa in dopamine-denervated rats. Synapse, 2002, 44, 166-174.	0.6	62
61	Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease. Neurological Sciences, 2001, 22, 59-60.	0.9	22
62	Cocaine effects on gene regulation in the striatum and behavior. NeuroReport, 2000, 11, 2395-2399.	0.6	49
63	Expression of Functional Leptin Receptors in Rodent Leydig Cells1. Endocrinology, 1999, 140, 4939-4947.	1.4	229
64	Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice. Neuroscience, 1999, 90, 1021-1029.	1.1	16
65	Effect of MK 801 on priming of D1-dependent contralateral turning and its relationship to c-fos expression in the rat caudate-putamen. Behavioural Brain Research, 1996, 79, 93-100.	1.2	17
66	Modulation of dopamine D1-mediated turning behavior and striatal c-fos expression by the substantia nigra. Synapse, 1995, 19, 233-240.	0.6	19
67	Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats. Synapse, 1994, 18, 288-293.	0.6	27
68	l-Dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors. Brain Research, 1993, 623, 334-336.	1.1	51
69	Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses. Neuroscience, 1993, 53, 673-678.	1.1	49